A literature review was conducted to assess the evidence regarding the risks and benefits of oestrogen therapy in climacteric women. Consideration was given to the route of administration, effects on lipid levels, the skin and urinary symptoms, endometrial cancer, mortality and replacement therapy. It was concluded from the data examined that properly administered oestrogen treatment does not increase the risk of endometrial cancer and that the relative risk of death in oestrogen users aged over 40 is markedly lower than than in non-users.
View Article and Find Full Text PDFActa Obstet Gynecol Scand
May 1985
Discussion on the advantages of abdominal hysterectomy versus supravaginal uterine amputation has concentrated on the incidence of carcinoma in the remaining stump, mortality, and other serious complications. During the period 1952-78 we have performed 2712 supravaginal amputations with peroperative electrocoagulation of endocervical mucosa. The incidence of stump carcinoma was 0.
View Article and Find Full Text PDFSkinfold thickness was measured in 130 post-menopausal women treated with long-term hormone therapy. One group of 50 women took oestradiol valerate 2 mg/day for 3 wk out of 7, a second group comprising 19 women received oestriol succinate 2 mg/day and the remaining group of 61 women used oestradiol valerate 2 mg/day combined sequentially with norgestrel 0.5 mg/day.
View Article and Find Full Text PDFOestradiol and naproxen were compared in a double-blind, cross-over study of 20 women suffering from climacteric symptoms. Subjective symptoms were assessed before and after treatment. In addition, serum levels of prostaglandin precursors and of certain other free fatty acids were determined.
View Article and Find Full Text PDF